Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side?

Osteoporos Int. 2010 Apr;21(4):701-3. doi: 10.1007/s00198-009-0986-y. Epub 2009 Jun 27.

Abstract

Introduction: Atypical fractures of the femoral diaphysis have recently been associated with alendronate therapy (Neviaser et al. J Orthop Trauma 22(5):346-350, 2008; Kwek et al. Injury 39:224-231, 2008; Lenart et al. N Engl J Med 358:1304-1306, 2008).

Methods: In many cases, fractures have occurred bilaterally prompting debate regarding appropriate screening of the unaffected side (Kwek et al. N Engl J Med 359(3):316-317, 2008).

Case report: We report a case of sequential, bilateral, femoral diaphysis fractures associated with prolonged alendronate therapy and the failure to predict the subsequent fracture of the contralateral side despite radiological imaging.

Discussion: We review the current literature and discuss potential management strategies.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Alendronate / adverse effects*
  • Bone Density Conservation Agents / adverse effects*
  • Female
  • Femoral Fractures / chemically induced*
  • Femoral Fractures / diagnostic imaging
  • Femoral Fractures / pathology
  • Femoral Fractures / prevention & control
  • Fractures, Stress / chemically induced
  • Fractures, Stress / diagnostic imaging
  • Fractures, Stress / prevention & control
  • Humans
  • Middle Aged
  • Radiography

Substances

  • Bone Density Conservation Agents
  • Alendronate